###begin article-title 0
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Lack of regulation of 11beta-hydroxysteroid dehydrogenase type 1 during short-term manipulation of GH in patients with hypopituitarism
###end article-title 0
###begin title 1
Objective
###end title 1
###begin p 2
###xml 84 92 84 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 381 388 372 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Evidence from long-term clinical studies measuring urinary steroid ratios, and from in vitro studies, suggests that GH administered for longer than 2 months down-regulates 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), thereby reducing cortisol regeneration in liver and adipose tissue. We aimed to measure acute effects of GH on 11beta-HSD1 in liver and adipose tissue in vivo, including using a stable isotope tracer.
###end p 2
###begin title 3
Design
###end title 3
###begin p 4
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Observational studies of GH withdrawal and reintroduction in patients with hypopituitarism.
###end p 4
###begin title 5
Methods
###end title 5
###begin p 6
###xml 291 292 291 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 293 294 293 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 7 10 <span type="species:ncbi:9606">men</span>
Twelve men with benign pituitary disease causing GH and ACTH deficiency on stable replacement therapy for >6 months were studied after GH withdrawal for 3 weeks, and after either placebo or GH injections were reintroduced for another 3 weeks. We measured cortisol kinetics during 9,11,12,12-2H4-cortisol (d4-cortisol) infusion, urinary cortisol/cortisone metabolite ratios, liver 11beta-HSD1 by appearance of plasma cortisol after oral cortisone, and 11beta-HSD1 mRNA levels in subcutaneous adipose biopsies.
###end p 6
###begin title 7
Results
###end title 7
###begin p 8
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 62 63 62 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
GH withdrawal and reintroduction had no effect on 9,12,12-[2H]3-cortisol (d3-cortisol) appearance, urinary cortisol/cortisone metabolite ratios, initial appearance of cortisol after oral cortisone, or adipose 11beta-HSD1 mRNA. GH withdrawal increased plasma cortisol 30-180 min after oral cortisone, increased d4-cortisol clearance, and decreased relative excretion of 5alpha-reduced cortisol metabolites.
###end p 8
###begin title 9
Conclusions
###end title 9
###begin p 10
###xml 57 64 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 68 74 <span type="species:ncbi:9606">humans</span>
In this setting, GH did not regulate 11beta-HSD1 rapidly in vivo in humans. Altered cortisol metabolism with longer term changes in GH may reflect indirect effects on 11beta-HSD1. These data do not suggest that glucocorticoid replacement doses need to be increased immediately after introducing GH therapy to compensate for reduced 11beta-HSD1 activity, although dose adjustment may be required in the longer term.
###end p 10
###begin title 11
Introduction
###end title 11
###begin p 12
###xml 229 234 220 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1 bib2">(1, 2</xref>
###xml 248 251 239 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">(3)</xref>
###xml 475 478 460 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">(4)</xref>
###xml 538 544 523 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5 bib6">(5, 6)</xref>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) regenerates cortisol from inactive cortisone in liver and adipose tissue. It has been proposed that GH, via insulin-like growth factor-1 (IGF1), down-regulates 11beta-HSD1 (1, 2, reviewed in (3)); that increased 11beta-HSD1 in GH-deficient adults may contribute to their central obesity; and that introducing GH treatment in hypopituitary patients may decrease 11beta-HSD1 and precipitate adrenocortical insufficiency (4) or necessitate an alteration in glucocorticoid replacement (5, 6).
###end p 12
###begin p 13
###xml 93 101 90 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 168 174 162 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2 bib7">(2, 7)</xref>
###xml 198 201 192 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">(8)</xref>
###xml 212 219 206 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 318 333 309 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1 bib5 bib6 bib9 bib10 bib11 bib12">(1, 5, 6, 9&#8211;12)</xref>
###xml 395 402 383 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2 bib13">(2, 13)</xref>
###xml 507 510 495 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">(2)</xref>
###xml 610 618 595 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14 bib15">(14, 15)</xref>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
###xml 521 524 <span type="species:ncbi:9606">men</span>
A key question is whether changes in 11beta-HSD1 occur acutely after introducing GH therapy. In vitro, IGF1 down-regulates 11beta-HSD1 expression rapidly in adipocytes (2, 7) but not in hepatocytes (8). However, in vivo studies in GH-deficient patients have measured 11beta-HSD1 after a minimum of 2 months of therapy (1, 5, 6, 9-12), when indirect effects may affect 11beta-HSD1. In acromegaly (2, 13), changes in urinary cortisol metabolite ratios following withdrawal of octreotide occur after 4-8 weeks (2). In obese men, GH effects on 11beta-HSD1 were observed after 6 weeks but resolved after 4-9 months (14, 15).
###end p 13
###begin p 14
###xml 46 53 43 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 427 430 414 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">(6)</xref>
###xml 627 631 608 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">(11)</xref>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
Previous studies of GH effects on 11beta-HSD1 in vivo have relied almost exclusively on measuring urinary ratios of cortisol/cortisone metabolites; these are influenced by enzymes other than 11beta-HSD1, notably 5alpha- and 5beta-reductase, and have not been validated in patients receiving glucocorticoid replacement therapy. Although in one study GH administration reduced plasma cortisol after oral cortisone administration (6), plasma cortisol was also lower after oral hydrocortisone, suggesting mechanisms in addition to inhibition of 11beta-HSD1. However, in another study, GH reduced 11beta-HSD1 mRNA in adipose tissue (11).
###end p 14
###begin p 15
###xml 79 86 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 387 388 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 389 390 383 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 414 418 408 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">(16)</xref>
###xml 481 482 471 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 522 523 509 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 525 526 512 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 590 591 577 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 593 594 580 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 726 727 707 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 90 95 <span type="species:ncbi:9606">human</span>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
To test the hypothesis that GH/IGF1 regulates 11beta-HSD1 directly and acutely in vivo in human liver and adipose tissue, we studied patients with hypopituitarism during long-term GH therapy, after GH withdrawal for 3 and 6 weeks and after GH reintroduction for 3 weeks. To quantify the rate of cortisol regeneration by 11beta-HSD1 we used a steady-state tracer infusion with 9,11,12,12-2H4-cortisol (d4-cortisol) (16). During d4-cortisol infusion, there is removal of the 11alpha-2H by 11beta-HSD type 2 to form 9,12,12-[2H]3-cortisone (d3-cortisone) which is then regenerated to 9,12,12-[2H]3-cortisol (d3-cortisol) by 11beta-HSD1; d4-cortisol is not regenerated by 11beta-HSD1 since it is highly unlikely that a deuterium (2H) will be reintroduced in the 11alpha position. The dilution of d4-cortisol by d3-cortisol therefore indicates 11beta-HSD1 reductase activity. We also measured liver 11beta-HSD1 activity (by first pass conversion of orally administered cortisone to cortisol) and adipose 11beta-HSD1 mRNA (in subcutaneous adipose tissue biopsies).
###end p 15
###begin title 16
Subjects and methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 17
###begin p 18
Inclusion criteria: male; hypopituitarism due to benign disease; age 20-75 years; documented GH and ACTH deficiency; stable hormone replacement therapy, including GH and glucocorticoid for >6 months, achieving normal range serum IGF1. Exclusion criteria: acromegaly; anti-inflammatory glucocorticoid therapy by any route within 3 months; significant co-morbidity. Informed consent and local ethical committee approval were obtained.
###end p 18
###begin title 19
Protocol
###end title 19
###begin p 20
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
###xml 70 73 <span type="species:ncbi:9606">men</span>
###xml 220 223 <span type="species:ncbi:9606">man</span>
###xml 325 328 <span type="species:ncbi:9606">men</span>
Participants were randomly allocated to either of the two groups. Six men were studied taking their usual therapy ('baseline'), 3 weeks after withdrawal of GH therapy, and 3 weeks after reintroduction of GH therapy. One man withdrew after completing baseline and some measurements after 3 weeks of GH withdrawal. Another six men were studied at baseline, 3 weeks after withdrawal of GH therapy, and 6 weeks after withdrawal of GH therapy; placebo was administered during weeks 3-6.
###end p 20
###begin p 21
Measurements were made during three visits within the final 5 days of each phase. In one visit, a 24-h urine sample was collected; a blood sample was obtained at 0800 h after overnight fast and usual medication at 0700 h; anthropometric measurements were recorded; dual-energy X-ray absorptiometry was measured for body composition (LUNAR DPX-L scanner, Scanexport Medical, Helsingborg, Sweden); and a approximately300 mg gluteal subcutaneous adipose biopsy was obtained under local anaesthesia. On a second visit, after overnight fast and omission of morning medication, a single dose of 25 mg cortisone acetate was administered and plasma cortisol measured at intervals for 3 h. On a third visit, after overnight fast and omission of morning medication, d4-cortisol (Cambridge Isotopes, Andover, MA, USA) was infused at 20% molar percent excess in cortisol at 1.74 mg/h and blood sampled at intervals for 5 h.
###end p 21
###begin title 22
Laboratory assays
###end title 22
###begin p 23
###xml 237 245 227 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17 bib18">(17, 18)</xref>
Cortisol and its metabolites (5beta-tetrahydrocortisol (THF), 5alpha-THF, 5beta-tetrahydrocortisone, cortols, cortolones, and cortisone) were measured in 24-h urine samples by gas chromatography/mass spectrometry as previously described (17, 18).
###end p 23
###begin p 24
###xml 127 131 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">(18)</xref>
Plasma d4-cortisol, d3-cortisone and d3-cortisol were measured by gas chromatography/mass spectrometry as previously described (18) and tracer kinetics calculated using the mean of up to six measurements in steady state between 225 and 300 min of d4-cortisol infusion. Clearance of d4-cortisol was calculated as (infusion rate)/(concentration). Rate of appearance of d3-cortisol was calculated as (d4-cortisol infusion rate)/(d4-cortisol:d3-cortisol ratio).
###end p 24
###begin p 25
###xml 267 271 267 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">(19)</xref>
RNA was extracted from 100 mg of tissue, oligo dT-primed cDNA synthesised, and transcripts quantified in triplicate using Real-Time PCR with a LightCycler 480 and Mastermix (Roche) and primer-probe sets from Applied Biosystems (Cheshire, UK), as previously described (19). Results are expressed as a ratio of transcript level to the mean of cyclophylin A and 18S.
###end p 25
###begin p 26
Plasma cortisol was measured by RIA (ImmunChem, MP Biomedical, High Wycombe, UK), immunoluminetric methods were used to measure serum IGF1 (Nichols Advantage Specialty System, Nichols Institute Diagnostics, San Juan Capistrano, CA, USA) and insulin (ADVIA Centaur Insulin Ready Pack, Bayer Corporation). Enzymatic methods were used to measure plasma glucose (GLU, Roche/Hitachi Roche Diagnostics GmbH), free fatty acids (FFA; NEFA C, WAKO Chemicals GmbH, Neuss, Germany) and triglycerides (TG, Roche/Hitachi Roche Diagnostics GmbH).
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
###xml 43 44 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 216 224 216 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16 bib18">(16, 18)</xref>
###xml 310 313 310 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">(6)</xref>
###xml 331 336 329 334 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s.e.m</sc>
###xml 393 394 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 541 549 539 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 567 568 565 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 770 771 768 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 910 918 908 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 926 927 924 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1110 1111 1108 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1111 1112 1109 1110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sub>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
###xml 738 746 <span type="species:ncbi:9606">patients</span>
A power calculation showed that a study of n=6 had 85% power (n=12 has >98% power) to detect an 18% change in d3-cortisol generation in a paired two-tailed test, based on previously published variance of measurement (16, 18) and magnitude of effect of GH on cortisol levels after oral cortisone administration (6). Data are mean+/-s.e.m. Groups were compared at baseline by unpaired Student's t-tests. Effects of GH withdrawal and reintroduction were assessed by one-way repeated measures ANOVA within each group of six patients followed by post hoc paired Student's t-tests, if appropriate. Furthermore, the effect of the 3-week withdrawal of GH was tested in a combined analysis of 'baseline' and the '3-week withdrawal' data in all 12 patients using paired Student's t-tests. Multiple cortisol measurements after oral cortisone administration were analysed by factorial repeated measures ANOVA, followed by post hoc paired t-tests at individual time points, if appropriate; curves were also fitted using Kinetica software (Thermo Scientific, Waltham, MA, USA) to derive an initial appearance rate constant (Ka).
###end p 28
###begin title 29
Results
###end title 29
###begin p 30
###xml 72 73 72 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 100 101 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 549 556 549 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
Patients had hypopituitarism after removal of benign pituitary adenoma (n=11) or craniopharyngioma (n=1). All patients were receiving substitution therapy with glucocorticoids (10 hydrocortisone, 2 cortisone acetate), thyroxine and testosterone. Five patients were receiving desmopressin. At baseline, the group randomly selected for prolonged GH withdrawal had higher fasting plasma triglycerides and tended to have higher body mass index, % body fat and fasting insulin levels than the group selected for GH withdrawal followed by reintroduction (Table 1).
###end p 30
###begin p 31
###xml 175 182 175 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 309 310 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 383 384 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 441 448 433 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 259 271 <span type="species:ncbi:9606">participants</span>
Withdrawal of GH resulted in a substantial fall in IGF1 after 3 weeks which was sustained after 6 weeks. Reintroduction of GH restored IGF1 to baseline values within 3 weeks (Table 1). Withdrawal of GH after 3 weeks also reduced fasting plasma FFA (in all 12 participants, from 0.55+/-0.05 to 0.40+/-0.04 mM, P=0.02) and triglycerides (in all 12, from 1.55+/-0.33 to 1.32+/-0.30 mM, P=0.04), which were lower after 6 weeks of GH withdrawal (Table 1). Reintroduction of GH prevented this decline in triglycerides. After 6 weeks of GH withdrawal the percentage of body fat increased and diastolic blood pressure decreased, but there were no other measured changes in glucose/insulin homeostasis or body composition.
###end p 31
###begin p 32
###xml 98 105 98 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
With exogenous glucocorticoid therapy, urinary cortisol metabolite excretion was highly variable (Table 1). There were no differences between groups in indices of overall 11beta-HSD activity or renal 11beta-HSD2 activity. However, the ratio of 5alpha-THF/cortisol, which reflects 5alpha-reductase activity in the liver, was decreased after 6 weeks GH withdrawal; the reintroduction of GH prevented this decline.
###end p 32
###begin p 33
###xml 44 51 44 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 56 62 56 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
###xml 358 370 <span type="species:ncbi:9606">participants</span>
Kinetics of d4- and d3-cortisol is shown in Table 1 and Fig. 1A. By chance, d3-cortisol generation rate was higher at baseline in the group randomised to GH reintroduction. The d4-cortisol clearance increased after 6 weeks of GH withdrawal. The d3-cortisol regeneration rate was not affected by GH withdrawal or reintroduction in either group or when all 12 participants were included.
###end p 33
###begin p 34
###xml 108 114 108 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
###xml 94 106 <span type="species:ncbi:9606">participants</span>
Cortisol levels following oral cortisone were higher after 3 weeks of GH withdrawal among all participants (Fig. 1B), and tended to rise further after 6 weeks GH withdrawal and revert to baseline values on reintroduction of GH. However, these changes occurred between 30 and 180 min and did not reflect the initial rate of appearance of cortisol <25 min after cortisone administration.
###end p 34
###begin p 35
###xml 93 100 90 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
Adipose mRNA transcripts for 11beta-HSD1 were unaffected by GH withdrawal or reintroduction (Table 1). Similarly, there were no changes in transcript levels of other genes thought to influence glucocorticoid signalling in adipose tissue: hexose-6-phosphate dehydrogenase, GRalpha and 5alpha-reductase type 1.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 85 92 82 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 616 619 607 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">(3)</xref>
###xml 103 109 <span type="species:ncbi:9606">humans</span>
###xml 128 131 <span type="species:ncbi:9606">men</span>
This is the first study to dissect acute effects of GH on 11beta-HSD1 using specific in vivo assays in humans. It shows that in men with hypopituitarism, withdrawal of GH for up to 6 weeks, or reintroduction of GH for 3 weeks, has no effect on 11beta-HSD1 in the whole body (d3-cortisol appearance rate and urinary cortisol/cortisone metabolite ratios), in liver (initial rate of cortisol appearance following oral cortisone) or in subcutaneous adipose tissue (transcript levels). These findings do not support the inference from previous long-term studies that GH acts through IGF1 directly to suppress 11beta-HSD1 (3).
###end p 37
###begin p 38
###xml 730 734 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">(20)</xref>
GH withdrawal increased plasma cortisol concentrations for 30-180 min after oral cortisone, but the lack of change in total urinary cortisol metabolite excretion suggests that the consequences for cortisol bioavailability are minor. It appears that the elevated plasma cortisol depends on factors other than 11beta-HSD1 activity, since the initial rate of cortisol appearance was unaltered, and there was no associated change in d3-cortisol generation. 5alpha-Reductase activity (assessed by urinary 5alpha-THF/cortisol ratio) decreased, and d4-cortisol clearance paradoxically increased, on prolonged GH withdrawal, suggesting that GH affects other cortisol-metabolising enzymes. Alternatively, GH may influence gastric emptying (20).
###end p 38
###begin p 39
###xml 409 413 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">(11)</xref>
###xml 632 636 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">(19)</xref>
###xml 787 794 774 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9 bib10">(9, 10)</xref>
GH withdrawal for 6 weeks was associated with a fall in plasma FFA and triglycerides and modest increase in body fat content without measurable changes in glucose/insulin homeostasis. This occurred in the absence of changes in 11beta-HSD1, making it less likely that GH effects on 11beta-HSD1 are a primary mediator of abnormal body composition in GH deficiency. Changes in 11beta-HSD1 mRNA in adipose tissue (11) with prolonged GH therapy may reflect indirect effects; although these might perhaps be mediated by alterations in body composition and insulin signalling, as we have described in subjects receiving PPARgamma agonists (19), previous studies have not associated changes in urinary cortisol/cortisone metabolite ratios with changes in insulin sensitivity or body fat content (9, 10).
###end p 39
###begin p 40
###xml 619 620 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 115 123 <span type="species:ncbi:9606">patients</span>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
###xml 950 958 <span type="species:ncbi:9606">patients</span>
The strength of these studies lies in the detailed assessment of cortisol metabolism and the paired analyses of 12 patients, which is a comparable sample size to that used in most previous studies in this area, and which we calculated gives ample statistical power to detect differences of the magnitude observed in previous studies. Weaknesses include: the fact that this group of patients had been exposed to chronic GH therapy in advance of the study, and GH was only deficient for 3 weeks, so that effects of GH (re)introduction may have been underestimated; the sample size was small for the subgroups at 6 weeks (n=6 and 5 per group); and the chance differences at baseline between these groups, e.g. in d3-cortisol generation and plasma triglycerides. As a result, direct comparisons at week 6 between subjects with and without GH reintroduction were avoided. The d4-cortisol tracer has been used extensively in healthy volunteers, but not in patients with glucocorticoid deficiency; we elected to limit our analysis to results which are entirely derived from the exogenous deuterated tracer infusion, and have not described the more variable results for endogenous cortisol production and metabolism.
###end p 40
###begin p 41
Extrapolation from small exploratory studies must always be cautious, but an important clinical implication of these findings is that these data do not support the concept that the dose of glucocorticoid replacement therapy needs to be adjusted upwards in the short-term following introduction of GH to compensate for a fall in 11beta-HSD1 activity. Although glucocorticoid dosing should be reassessed after medium to long-term GH therapy, further studies are required to clarify the need for dose adjustment in the short term.
###end p 41
###begin title 42
Declaration of interest
###end title 42
###begin p 43
B R Walker is an inventor on patents owned by the University of Edinburgh relating to 11beta-HSD1 inhibitors. The other authors have no conflicts of interest to declare.
###end p 43
###begin title 44
Funding
###end title 44
###begin p 45
This work was supported by the British Heart Foundation and University of Gothenburg.
###end p 45
###begin title 46
Acknowledgements
###end title 46
###begin p 47
We are grateful to Alison Rutter, Anna-Lena Jonsson and Ingrid Hansson and the staff of the Wellcome Trust Clinical Research Facility Mass Spectrometry Core Laboratory in Edinburgh for technical assistance. GH and placebo were kindly provided by NovoNordisk.
###end p 47
###begin title 48
References
###end title 48
###begin article-title 49
The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults
###end article-title 49
###begin article-title 50
###xml 109 116 106 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 121 129 118 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies
###end article-title 50
###begin article-title 51
Modulation of glucocorticoid metabolism by the growth hormone-IGF-1 axis
###end article-title 51
###begin article-title 52
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients
###end article-title 52
###begin article-title 53
The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11beta-hydroxysteroid dehydrogenase activity
###end article-title 53
###begin article-title 54
###xml 101 109 <span type="species:ncbi:9606">patients</span>
The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement
###end article-title 54
###begin article-title 55
Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines
###end article-title 55
###begin article-title 56
###xml 80 83 <span type="species:ncbi:10116">rat</span>
###xml 88 93 <span type="species:ncbi:9606">human</span>
Regulation of 11beta-hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes
###end article-title 56
###begin article-title 57
Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity
###end article-title 57
###begin article-title 58
###xml 98 106 <span type="species:ncbi:9606">patients</span>
Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients
###end article-title 58
###begin article-title 59
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Growth hormone (GH) substitution in GH-deficient patients inhibits 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue
###end article-title 59
###begin article-title 60
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Growth hormone replacement inhibits renal and hepatic 11beta-hydroxysteroid dehydrogenases in ACTH-deficient patients
###end article-title 60
###begin article-title 61
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly
###end article-title 61
###begin article-title 62
GH effect on enzyme activity of 11betaHSD in abdominal obesity is dependent on treatment duration
###end article-title 62
###begin article-title 63
###xml 111 119 <span type="species:ncbi:9606">patients</span>
Low-dose growth hormone inhibits 11beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity
###end article-title 63
###begin article-title 64
###xml 70 77 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Distinguishing the activities of 11beta-hydroxysteroid dehydrogenases in vivo using isotopically labelled cortisol
###end article-title 64
###begin article-title 65
###xml 156 163 153 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11beta-hydroxysteroid dehydrogenase in vivo
###end article-title 65
###begin article-title 66
###xml 89 95 <span type="species:ncbi:9606">humans</span>
The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans
###end article-title 66
###begin article-title 67
###xml 160 163 <span type="species:ncbi:9606">men</span>
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men
###end article-title 67
###begin article-title 68
Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study
###end article-title 68
###begin p 69
###xml 348 355 345 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 723 728 718 723 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s.e.m</sc>
###xml 878 886 873 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 904 905 899 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 950 951 945 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1080 1081 1075 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1088 1096 1083 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 1229 1230 1224 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1338 1339 1333 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1373 1374 1368 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1427 1435 1422 1430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 1539 1540 1534 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1540 1541 1535 1536 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sub>
###xml 1556 1563 1551 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
###xml 936 948 <span type="species:ncbi:9606">participants</span>
Effects of GH withdrawal and re-introduction on 11beta-HSD1 conversion of cortisone to cortisol. (A) Rate of appearance (Ra) of d3-cortisol during steady-state d4-cortisol infusion. Results are shown for individual patients allocated to 6 weeks GH withdrawal (squares) or GH withdrawal and reintroduction (circles). Summary statistics are shown in Table 1. Results varied widely among patients with hypopituitarism but by chance, Ra of d3-cortisol was higher in the group allocated with GH reintroduction. However, there were no significant changes in Ra of d3-cortisol on GH withdrawal for 3 or 6 weeks, or on GH reintroduction for 3 weeks. (B) First pass conversion of cortisone to cortisol in liver. Results show mean+/-s.e.m. plasma cortisol concentrations after oral administration of cortisone acetate 25 mg at time=0. Results were compared by repeated measures ANOVA and post hoc paired Student's t-tests, if appropriate. In all participants (n=12), there was a difference between baseline (open circle, solid line) and 3 weeks of GH withdrawal (open squares, solid lines; P<0.03; post hoc tests significant at time =150 and 180). There was no additional significant change in plasma cortisol after 6 weeks GH withdrawal (n=6; filled squares, dotted lines). However, cortisol values were reduced by reintroduction of GH treatment (n=6; filled circles, dotted lines; P<0.02 by ANOVA, no single time-points significant in post hoc tests). Curves from each individual were fitted with Kinetica software: the appearance rate constants (Ka) are shown in Table 1 and did not differ between groups.
###end p 69
###begin p 70
Effects of GH withdrawal and re-introduction.
###end p 70
###begin p 71
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 9 15 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 15 16 10 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 72 85 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8225;</sup>
###xml 85 86 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 93 105 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#167;</sup>
###xml 105 106 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 113 121 85 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8741;</sup>
###xml 121 122 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 216 230 181 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#182;</sup>
###xml 230 231 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
*P<0.05, daggerP<0.01 for differences between study groups at baseline; double daggerP<0.05, section signP<0.01, parallelP<0.001 for effects of GH withdrawal (i.e. differences from baseline) within each study group; paragraph signP<0.01 for effects of GH reintroduction (i.e. differences from 3 week withdrawal) in study group 1. BMI, body mass index; BP, blood pressure; FFA, free fatty acids; Ra, rate of appearance; GR, glucocorticoid receptor.
###end p 71
###begin p 72
Note that one subject withdrew from the GH reintroduction group, so that mean data may appear to differ from values after 3 weeks withdrawal, but only statistically significant differences are highlighted.
###end p 72
###begin p 73
Total cortisol excretion was calculated from the sum of 5beta-THF, 5alpha-THF and THE. The balance between 11beta-HSD activities in all tissues was assessed as the ratio of (5beta-THF +5alpha-THF)/THE. Renal 11beta-HSD type 2 activity was assessed as urinary cortisol/cortisone ratio. The balance of 5alpha- and 5beta-reductases was assessed by the ratio 5beta-THF/5alpha-THF. 5alpha- and 5beta-reduction of cortisol was also assessed by 5alpha-THF/cortisol and 5beta-THF/cortisol ratios.
###end p 73

